Protalix Biotherapeutics पी/ई अनुपात 2024

Protalix Biotherapeutics क्या कर रहा है?

Protalix Biotherapeutics Inc is a biopharmaceutical company founded in 1993. Its headquarters is located in Karmiel, Israel. The company's main goal is to develop innovative drugs for the treatment of various diseases based on plant cell cultures. Protalix Biotherapeutics Inc's business model focuses on researching and developing drugs for diseases where there has been no cure. The company relies on an advanced technology platform that allows the use of plant cell cultures for the production of biopharmaceutical products. This method is not only cost-effective compared to other methods, but it also enables the production of drugs in larger quantities. Protalix Biotherapeutics Inc is divided into several divisions, including research, development, and manufacturing of drugs for lysosomal storage diseases, hematological and rheumatological diseases, as well as vascular anomalies and infectious diseases. Lysosomal storage diseases, for which Protalix Biotherapeutics Inc develops drugs, are inherited metabolic disorders. These diseases are rare and mostly occur in children. Affected individuals cannot produce or produce enzymes insufficiently, leading to an accumulation of waste products in the cells. These diseases are often severe and can lead to death if untreated. Examples of lysosomal storage diseases for which Protalix Biotherapeutics Inc develops drugs include Gaucher disease, Fabry syndrome, Pompe disease, and mucopolysaccharidosis type I. In the field of hematological and rheumatological diseases, Protalix Biotherapeutics Inc develops drugs for diseases such as hemophilia, rheumatoid arthritis, and Crohn's disease. Hemophilia is an inherited disease where blood clotting factor VIII or IX is missing or insufficiently produced. Rheumatoid arthritis is an inflammatory joint disease that often occurs in the elderly. Crohn's disease is a chronic inflammatory bowel disease that can lead to severe diarrhea. For the treatment of vascular anomalies, Protalix Biotherapeutics Inc is developing a drug called PRX-102. These diseases affect the body's vascular system and can cause dangerous bleeding. PRX-102 is a protein replacement therapy that replaces the body's production of the missing enzyme. In the field of infectious diseases, Protalix Biotherapeutics Inc is developing a drug called OPRX-106. This drug is an immunomodulator used to treat autoimmune diseases where the body's immune system attacks its own tissues. One of the main products offered by Protalix Biotherapeutics Inc is the drug Elelyso. This drug is used to treat Gaucher disease. Elelyso is the first drug approved by the US Food and Drug Administration (FDA) based on plant cell cultures. The drug is available in the US, Israel, and Brazil. Another important product of Protalix Biotherapeutics Inc is the drug PRX-102. This drug is still in the clinical development phase. PRX-102 is used to treat Fabry syndrome and is a protein replacement therapy that replaces the body's production of the missing enzyme. Overall, Protalix Biotherapeutics Inc is an innovative biopharmaceutical company specializing in the development of drugs for rare and serious diseases. The advanced technology platform based on plant cell cultures allows for effective and cost-efficient production of biopharmaceutical products. The company's different divisions allow it to cater specifically to the needs of patients with lysosomal storage diseases, hematological and rheumatological diseases, as well as vascular anomalies and infectious diseases. Protalix Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.